ruthenium has been researched along with Prostatic Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Carrion, C; Gallardo-Villagrán, M; Léger, DY; Liagre, B; Martin, F; Ouk, C; Paulus, L; Therrien, B | 1 |
| Bajo, AM; Bryszewska, M; de la Mata, FJ; García-Gallego, S; Gómez, R; Ionov, M; Ortega, P; Sanz Del Olmo, N | 1 |
| Giri, B; Kumbhakar, S; Maji, S; Misra, A; Muley, A; Saini, T; Selvan K, K | 1 |
| Bryszewska, M; Carmena, MJ; Gómez, R; Holota, M; Ionov, M; Javier de la Mata, F; Maroto-Diaz, M; Ortega, P; Quintana, S; Sanz Del Olmo, N | 1 |
| Aissa, AF; Antunes, LMG; Batista, AA; De Grandis, RA; Machado, ART; Oliveira, KM; Pavan, FR; Santos, PWDSD | 1 |
| Gano, L; Garcia, MH; Gonçalves, MS; Jorge, TF; Marques, F; Martins, M; Matos, AP; Morais, TS; Pinheiro, T; Tomaz, AI; Tortosa, F; Valente, A | 1 |
| Gou, S; Li, X; Liu, N; Sun, S; Wang, X; Wang, Z; Zhang, W; Zhao, J | 1 |
| Chen, T; Lai, H; Liu, C; Wang, X; Zeng, D; Zhang, Q | 1 |
| Aguilera, RJ; Martínez, A; Robles-Escajeda, E; Sánchez-Delgado, RA; Varela-Ramirez, A | 1 |
| Gao, Q; Li, C; Li, Z; Qi, H; Shan, M; Wang, J; Yang, H; Zhang, C | 1 |
| Callahan, BP; Herroon, MK; Kodanko, JJ; Li, A; Podgorski, I; Scott, EE; Turro, C; White, JK; Yadav, R | 1 |
11 other study(ies) available for ruthenium and Prostatic Neoplasms
| Article | Year |
|---|---|
The Effect of Photosensitizer Metalation Incorporated into Arene-Ruthenium Assemblies on Prostate Cancer.
Topics: Animals; Apoptosis; Drug-Related Side Effects and Adverse Reactions; Gastropoda; Humans; Male; Neoplasms, Second Primary; Photosensitizing Agents; Prostatic Neoplasms; Ruthenium | 2023 |
Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclopentanes; Dendrimers; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Organometallic Compounds; Prostatic Neoplasms; Ruthenium; Silanes; Structure-Activity Relationship | 2020 |
Near-IR light-induced photorelease of nitric oxide (NO) on ruthenium nitrosyl complexes: formation, reactivity, and biological effects.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coordination Complexes; Crystallography, X-Ray; Humans; Light; Male; Nitric Oxide; Photolysis; Photosensitizing Agents; Prostatic Neoplasms; Ruthenium | 2020 |
Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dendrimers; HeLa Cells; Humans; Male; Mice; Mice, Nude; Organometallic Compounds; PC-3 Cells; Prostatic Neoplasms; Ruthenium; Silanes | 2020 |
Novel lawsone-containing ruthenium(II) complexes: Synthesis, characterization and anticancer activity on 2D and 3D spheroid models of prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cattle; Cell Line, Tumor; Cell Movement; Coordination Complexes; DNA; Humans; Intercalating Agents; Male; Naphthoquinones; Prostatic Neoplasms; Reactive Oxygen Species; Ruthenium; Spheroids, Cellular | 2019 |
Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Coordination Complexes; Cyclopentanes; Dose-Response Relationship, Drug; Humans; Liver; Male; Prostatic Neoplasms; Ruthenium | 2019 |
Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coordination Complexes; Humans; Light; Magnetic Resonance Spectroscopy; Male; Microscopy, Atomic Force; Nitriles; PC-3 Cells; Photolysis; Prodrugs; Prostatic Neoplasms; Receptors, Androgen; Ruthenium; Tosyl Compounds | 2019 |
Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling.
Topics: Cell Degranulation; Cytotoxicity, Immunologic; DNA Damage; Fas Ligand Protein; fas Receptor; Humans; Immunotherapy; Killer Cells, Natural; Male; Prostatic Neoplasms; Reactive Oxygen Species; Receptors, Death Domain; Ruthenium; Selenium; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2019 |
Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Clotrimazole; DNA, Neoplasm; Humans; Ketoconazole; Male; Prostatic Neoplasms; Ruthenium | 2013 |
Electrogenerated chemiluminescence biosensing for the detection of prostate PC-3 cancer cells incorporating antibody as capture probe and ruthenium complex-labelled wheat germ agglutinin as signal probe.
Topics: Antibodies; Biosensing Techniques; Carbon; Electrodes; Humans; Luminescence; Male; Molecular Probes; Organometallic Compounds; Prostatic Neoplasms; Ruthenium; Tumor Cells, Cultured; Wheat Germ Agglutinins | 2015 |
Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Survival; Coordination Complexes; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Light; Male; Molecular Structure; Prostatic Neoplasms; Ruthenium; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship | 2017 |